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Abstract
Background: Multiple myeloma (MM) is a clonal B-cell disorder with many immunological
disturbances. The aim of this work was to assess whether some of food antigens contribute to the
imbalance of immune response by screening the sera of MM patients for their immunoreactivity to
food constituent gliadin, to tissue transglutaminase-2 (tTG-2) and to Ro/SSA antigen.
Sera from 61 patients with MM in various stages of disease, before, or after some cycles of
conventional therapy were analyzed by commercial Binding Site ELISA tests. The control group
consisted of 50 healthy volunteers. Statistical analysis of data obtained was performed by Mann
Whitney Test.
Results: The higher serum IgA immunoreactivity to gliadin was found in 14/56 patients and in one
of control people. The enhanced serum IgG immunoreactivity to gliadin was found in only two of
tested patients and in two controls. The enhanced IgA immunoreactivity to tTG-2 was found in 10/
49 patients' sera, while 4/45 patients had higher serum IgG immunoreactivity. The enhanced serum
IgG immunoreactivity to RoSSÀ antigen was found in 9/47 analyzed MM patients' sera. Statistical
analysis of data obtained revealed that only the levels of anti-tTG-2 IgA immunoreactivity in patients
with MM were significantly higher than these obtained in healthy controls (P < 0.02)
Conclusion: Data obtained showed the existence of the enhanced serum immunoreactivity to
gliadin, tTG-2 and Ro/SSA antigens in some patients with MM. These at least partially could
contribute to the immunological imbalance frequently found in this disease.
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Multiple myeloma (MM) is a clonal B-cell disorder which
diagnosis comprise the examination of bone marrow for
plasma cell infiltration, detection and quantification of
monoclonal protein "M" component in the serum or
urine, and evidence of end-organ damage (hypercalcemia,
renal insufficiency, anemia or bone lesions). Many of the
laboratory parameters contribute to myeloma diagnosis
due to plenty of immunological disturbances [1]. It was
shown that the antibodies contained in M component
have various specificity to: some proteins, double-
stranded DNA, several antibiotics [2], and sometimes to
gliadin (and/or calreticulin?) [3].
As the enhanced levels of the serum antibodies to gliadin
are found in patients with celiac disease, as well as of anti-
bodies to transglutaminase-2 (TTG-2) [4,5], to calreticulin
[6,7] and Ro/SSA antigen [8], the aim of this work was the
screening of MM patients' sera for their immunoreactivity
to food constituent gliadin, and to autoantigens: tissue
transglutaminase-2 (tTG-2) and Ro/SSA antigen, in order
to assess whether immunoreactivity to mentioned anti-
gens at least partially contributes to the immunological
imbalance in multiple myeloma.
Methods
Patients
Sera from 61 patients with MM in various stages of dis-
ease, before or after some cycles of conventional therapy,
were analyzed for immunity to gliadin, tissue TTG-2, and
Ro/SSA antigen. Determination of serum IgA and IgG
immunoreactivity to gliadin (IU/ml), to tTG-2 (IU/ml), or
to Ro/SSA (IU/ml), was done by diagnostic, commercial
ELISA (Binding Site) tests. Briefly, 100 µl of diluted
(1:100) human sera, commercial controls and calibrators
were dispensed in appropriate wells of the plates provided
in the kit. During the first incubation, autoantibodies rec-
ognizing the antigen bind to it and all unbound proteins
were removed by washings. After that, purified peroxidase
labeled rabbit anti human IgA or IgG conjugate (100 µl)
which binds to the captured human autoantibodies was
added, and the excess unbound conjugate is removed by
washings. The conjugate was treated with TMB (3,3,5,5-
tetramethylbenzidine). The reaction was stopped by the
addition of phosphoric acid. The concentration of autoan-
tibodies was measured on ELISA reader at 450 nm. Cut
offs for each test was evaluated as the mean X+2 SD.
The control group consisted of 50 healthy volunteers (age
range was 27–58 years, 26 were female).
Statistical analysis of data obtained was performed by
Mann Whitney Test.
Experimental research that is reported in the manuscript
has been performed with the approval of the ethics com-
mittee of Institute of Oncology and Radiology of Serbia.
Results
Cut off values of anti-gliadin reactivity obtained analyzing
50 healthy sera were 3.46 IU/ml for IgA and 5.83 IU/ml
for IgG.
The elevated serum IgA immunoreactivity to gliadin was
found in 14/56 patients and in one of controls. From
these patients, 4 were with IgA myeloma and 4 were with
IgG myeloma, while 6 were without M component in
their sera.
Statistical analysis of data obtained revealed that the level
of anti-gliadin IgA immunoreactivity for patients with
MM was not significantly differ than that for controls (P =
0.052).
Surprisingly, the elevated IgG immunoreactivity to gliadin
was found only in two of tested MM patients sera and in
two of control people (Fig 1.) and both patients were with
IgG myeloma.
The antigliadin serum IgA and IgG immunoreactivity of healthy control  and of patients with yelomaFigure 1
The antigliadin serum IgA and IgG immunoreactivity 
of healthy controls and of patients with myeloma.
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healthy sera were 1.86 IU/ml for IgA and 6.17 IU/ml for
IgG.
As seen on Fig. 2.a. higher than cut off of IgA immunore-
activity to tTG was found in 10/49 patients and 2 of con-
trols. From 10 anti-tTg IgA positive patients 4 were with
IgA and 4 were with IgG myeloma, while 2 were without
M component in their sera. Statistical analysis of data
obtained revealed that the level of anti-tTG-2 IgA immu-
noreactivity in patients with myeloma was significantly
higher than that obtained in healthy controls (P < 0.02).
Sera from 4/45 patients and 3 controls had higher than
cut off value for IgG immunoreactivity (Fig. 2.b). All 4
anti-tTg IgG positive patients were with IgG MM.
Cut off values of anti-Ro/SSA IgG reactivity obtained ana-
lyzing 50 healthy sera was 3.59 IU/ml. The enhanced IgG
immunoreactivity to RoSSÀ antigen found in this work in
9/47 analyzed MM patients' sera (Fig. 3). These anti-
RoSSÀ IgG positive patients were: 2 with IgA, 5 with IgG,
and 2 without M component.
Discussion
In this work, the immunoreactivity to one of the food con-
stituents is found in some MM patients. It is manifested
through the enhanced levels of serum IgA immunoreactiv-
ity to gliadin. Data obtained by ELISA tests indicate that
especially anti-gliadin, IgA immunity is developed in
patients with MM. It seems that the elevated immunoreac-
tivities to gliadin could not be the consequence of over-
production of immmunoglobulins from M component,
because the enhanced antigliadin IgA immunoreactivity
was found in the serum of some of MM patients without
M component as well as in patients with IgG myeloma
too. It is also possible that in some patients serum
antigliadin immunoreactivities could be hidden in
immune complexes in circulation (CIC) and in these cases
this reactivity could not be revealed by ELISA test. One of
the solutions for this problem could be the electrophore-
sis of serum proteins performed in the alkaline conditions
pH = 8.6 i.e., in conditions which enables dissociation of
antibodies from antigen in CIC [9,10]; these antibodies
physically separated from the gliadin by electrophoresis
could then again react with gliadin (0.2%, or 0.4% in
0.5% SDS) in the test for immunofixation [3].
It must be mentioned that only the level of anti tTG-2 IgA
immunoreactivity in patients with myeloma was signifi-
The anti-Ro/SSA serum IgG immunoreactivity of healthy con-trols and of patients with myelomaFigure 3
The anti-Ro/SSA serum IgG immunoreactivity of 
healthy controls and of patients with myeloma.
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The anti tTG serum IgA and IgG immunoreactivity 
of healthy controls and of patients with myeloma.
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Besides, our results show that autoimmune determinants
as the enhanced immunity to tTG-2, and to Ro/SSA anti-
gen, which are present in patients with gluten intolerance
[4,5] and autoimmune diseases [8] respectively, are
present in some patients with MM, too.
Immunoreactivity to some of these antigens was also
found in few of healthy controls, indicating that the
immunoreactivities to tTG or to Ro/SSA antigens, or to
gliadin are not strictly specific for MM, but that they are
only one part of the complex immunological disturbances
found in this disease. Findings from this work are in
accordance with the previously published reports [11-14]
pointing to the partial immunological similarity between
MM and celiac disease.
This work indicates that gliadin as food antigen could at
least partially contribute to the plethora of immunologi-
cal disturbances in some patients with MM. Due to the
aminoacid sequence equality or high homology between
α-gliadin and γ-gliadin and C albicans–hyphal wall pro-
tein 1 (HWP1), and with calreticulin, it is also possible
that the determined immunoreactivity with gliadin is in
part the consequence of the cross reactivity with men-
tioned proteins [15].
Conclusion
Data from this work showed the existence of the enhanced
serum immunoreactivity to gliadin, tTG-2 and Ro/SSA
antigens in some patients with MM and set up the ques-
tion whether MM is also on the list of malignant diseases
which are associated with immunological aspect of gluten
intolerance [16-19]. They call for the additional research
to elucidate the clinical importance of both: the elevated
humoral immunity to food antigens and to some autoan-
tigens in patients with MM.
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